XTORO is a New Chemical Entity that is FDA approved for the treatment of acute otitis externa, commonly known as "swimmer’s ear", caused by susceptible strains of Pseudomonas aeruginosa and ...

Fonseca Biosciences ("Fonseca") announced today an agreement with MerLion Pharmaceuticals GmbH granting Fonseca the exclusive rights to market and distribute XTORO ® (finafloxacin otic suspension ...

Fonseca is stepping up to deliver a new option, XTORO, which is approved by the US Food and Drug Administration (FDA) for the treatment of AOE. Finafloxacin, the active ingredient in XTORO ...

0.3% in the United States. Millions of Americans suffer from acute otitis externa (AOE), better known as swimmer’s ear. Fonseca is stepping up to deliver a new option, XTORO, which is approved by the ...

XTORO is a New Chemical Entity that is FDA approved for the treatment of acute otitis externa, commonly known as "swimmer’s ear", caused by susceptible strains of Pseudomonas aeruginosa and ...